Chronic hepatitis B virus infection

This study looks at whether a medicine called peginterferon alfa, alone or with other antivirals, can clear the hepatitis B surface antigen from the blood. A total of 10,000 adults aged 18-65 who have used interferon before and still have low antigen levels will take the treatmen…

This early-stage trial tests an injection called TVAX-028 in adults with chronic hepatitis B. The study checks if the drug is safe and how the body processes it. Participants receive either TVAX-028 with an adjuvant or the adjuvant alone, at different dose levels. The goal is to …

This trial tests whether ursodeoxycholic acid (UDCA), a bile acid supplement, can speed up liver regeneration in adults receiving a living-donor liver transplant. Participants take UDCA or a placebo starting at least 10 days before surgery and continuing for 10 days after. Resear…

This phase 2 trial tests an experimental drug called AHB-137 in 70 adults with chronic hepatitis B who are already on antiviral pills. The drug is given as a shot under the skin. The goal is to see if it can lower the virus to undetectable levels and allow some people to stop the…

This phase 2 trial tests an injection called AHB-137 in adults with chronic hepatitis B who have not yet received treatment. The study compares AHB-137 to a placebo to see if it can lower the amount of hepatitis B virus in the blood and reduce a key marker of infection (HBsAg). P…

This Phase 2 trial tests an injection called AHB-171 in 138 people with chronic hepatitis B. The goal is to see if it can lower hepatitis B surface antigen and viral DNA to very low levels, potentially leading to a functional cure. Participants include those who have never been t…

This early-phase study tests a new injectable drug called AHB-171 in 144 adults with chronic hepatitis B. The main goals are to check the drug's safety and how the body processes it. Some participants will also take standard oral antivirals. The study is not yet recruiting.

This study tests an experimental injection called HRS-5635 in adults with chronic hepatitis B whose virus is already controlled by daily pills. The goal is to see if the injection can help the body clear the virus so patients can safely stop all hepatitis B medications. About 540…

This early-stage study tests a single injection of AHB-137 in 32 people with chronic hepatitis B, some with mild to moderate liver dysfunction and some with normal liver function. Researchers will measure how the drug moves through the body and check for safety issues. The goal i…

This study compares remote robotic liver surgery to local robotic surgery to see if the remote approach is just as safe and effective. About 148 adults with liver disease will be randomly assigned to one of the two types of surgery. Researchers will track complications, recovery,…

This early-stage trial is testing a new drug called ACT500 in 24 people who have both fatty liver disease and chronic hepatitis B. The main goal is to check the drug's safety and how the body processes it at different doses. Participants will take ACT500 or a placebo daily, and r…

This phase 3 trial tests a new drug called GST-HG141 (Nairecovir) combined with standard antivirals in 576 adults with chronic hepatitis B. Participants have already completed 48 weeks of treatment in an earlier study. The goal is to see if the combination is safe and helps keep …

This early-phase study will test whether adding peginterferon alfa-2b to standard antiviral drugs can help prevent hepatitis B-related liver cancer from coming back after surgery. About 156 adults aged 18 to 65 will receive either the combination or antivirals alone. Researchers …

This study compares two common antibiotic combinations—vancomycin with piperacillin/tazobactam versus vancomycin with meropenem—to see which is less harmful to the kidneys. About 852 hospitalized adults with serious infections will be randomly assigned to one of the two combos. T…

This study tests whether adding Babao Dan Capsule (a traditional Chinese medicine) to standard antiviral treatment can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis who are at high risk. About 1,034 adults aged 18-65 with a specific TCM …

This study tests whether a medicine called ursodeoxycholic acid (UDCA) can help lower bilirubin levels in people with acute viral hepatitis (types A or E). Bilirubin is a waste product that builds up when the liver is inflamed, causing jaundice. The trial will compare 88 adults w…

This study tests an AI-powered assistant (Union-Agent) designed to encourage people with chronic hepatitis B who have been diagnosed but not yet treated to start antiviral medication. The study will enroll 2000 adults in China who are eligible for treatment but haven't started. T…

This study tests whether adding a traditional Chinese medicine called Biejia-Ruangan compound to standard antiviral therapy can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis. About 1,034 high-risk adults (based on a special score) will b…

This study tests whether giving two antiviral drugs—entecavir followed by pegylated interferon—can help children aged 3 to 6 with chronic hepatitis B achieve a functional cure (clearing the virus from the blood). About 80 children will be randomly assigned to receive either entec…

This study tests whether adding pegylated interferon to entecavir helps young children (ages 3-6) with chronic hepatitis B achieve a functional cure, meaning the virus becomes undetectable. Sixty children will receive either entecavir alone or entecavir followed by the combinatio…

This Phase 3 trial tests an injection called TVAX-008 for people with chronic hepatitis B. About 630 adults who have been on antiviral therapy for at least 6 months will receive either TVAX-008, a placebo, or an active comparator. The goal is to see if the treatment can clear hep…

This study will offer free hepatitis B testing to nearly 240,000 adults in Phichit, Thailand, who were born before 1992 and may have been infected before vaccines were available. Those who test positive will receive care and daily medication to control the virus and prevent liver…

This study tests whether a weekly injection of pegylated interferon alfa-2b for 48 weeks can help children and teens (ages 3–17) with chronic hepatitis B achieve a functional cure. The treatment group will be compared to an observation group receiving no drug or standard antivira…

This early-stage trial tests a new therapeutic vaccine (Hepadvax) in 40 adults with chronic hepatitis B. The vaccine is designed to boost the immune system to control or possibly clear the virus. Researchers will monitor safety, viral load, and immune responses compared to a stan…

This study checks if a simpler way to collect blood samples works as well as the standard method for the HepQuant DuO liver test. The test involves drinking a natural substance and taking blood samples 20 and 60 minutes later. Researchers will compare different blood collection t…

This study investigates how the experimental cancer drug atirmociclib is processed by the body in people with mild, moderate, or severe liver disease compared to those with healthy livers. Participants receive a single oral dose of the drug, and blood samples are taken over time …

This observational study will look at 10,000 adults in intensive care units (ICUs) around the world during a single 24-hour period. Researchers want to find out how common infections and antibiotic-resistant bacteria are, how they are treated, and how patients recover. No new tre…

This research project aims to understand why older adults get more infections and why those infections can be more serious. By following 23,000 people aged 60 and older, scientists will collect health data and samples like blood and stool to study how the immune system changes wi…

This phase 1 trial investigates how mild, moderate, and severe liver impairment affects the way the body processes a single inhaled dose of treprostinil palmitil, a drug used for certain lung conditions. The study enrolls about 30 adults with varying levels of liver function and …

This study tests new MRI techniques to measure blood flow and tissue details in the liver. Researchers will scan 110 people, including healthy volunteers and those with chronic liver disease or fibrosis, to see if these scans can reliably detect liver damage. The goal is to devel…

This early-stage study is testing a new medicine for overweight and obesity. The main goal is to see how the drug behaves in people with different levels of liver function, from normal to severely reduced. About 35 adults aged 18-80 will take a single dose, and researchers will m…

This study looks at whether lifestyle changes can reduce the risk of liver cancer in people already at high risk. Researchers will track changes in bile acids, gut bacteria, and liver health in 90 adults aged 50-90. The goal is to see if simple adjustments can make a lasting diff…

This early-stage study looks at how a single 25 mg dose of VC005 tablets behaves in people with mild or moderate liver impairment compared to healthy volunteers. The goal is to measure drug levels and safety. 24 participants will take one dose and be monitored closely.

This study will follow 1,000 adults who have liver or bile duct surgery at one hospital in Italy. Researchers will track complications, survival, and cancer recurrence for up to 5 years. The goal is to better understand what affects recovery and long-term health after these opera…

This early-stage study will give a single dose of MDR-001, a GLP-1 receptor agonist tablet, to 32 people: some with mild or moderate liver impairment and some with healthy livers. Researchers want to see how the drug moves through the body and if it is safe in people with liver i…

This early-stage study looks at how the drug anecatibin fumarate is processed in the body of people with and without liver problems. It will include 24 adults with lung cancer. The goal is to understand safety and drug levels, not to test if the drug works.

This study will follow 352 pregnant women with chronic hepatitis B to see how often their liver enzymes rise after giving birth. Researchers want to find out what factors predict these spikes, especially comparing those who took antiviral drugs during pregnancy to those who did n…

This early-stage study looks at how the drug GS1-144 moves through the bodies of women with and without liver problems. About 24 women aged 18 to 70 will take part. The goal is to measure drug levels and see if liver function affects them. No treatment is being tested.

This study looks at how the hepatitis B virus changes over time in people taking antiviral drugs. Researchers will analyze blood samples from 700 adults in Turkey to see if the virus becomes resistant to treatment. The goal is to help doctors choose the best medications for each …

This early-stage study looks at how the drug buagafuran (AF-5) behaves in people with liver impairment compared to those with normal liver function. Twenty-four adults will receive a single 30 mg dose, and researchers will measure drug levels in the blood and monitor safety. The …

This study aims to create an artificial intelligence (AI) system that can combine medical images (like CT and MRI scans) with patient records and lab results to help doctors more accurately diagnose diseases of the liver, gallbladder, and pancreas. The researchers will use data f…

This study looks at how the drug hydronidone moves through the body in people with different levels of liver function. Thirty adults with either normal liver function or varying degrees of liver impairment will take a single dose of the drug. The goal is to understand how liver h…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study will follow 300 adults with severe infections in the ICU to see how levels of specialized pro-resolving mediators (SPMs)—natural molecules that help stop inflammation—change over time. Researchers will use blood samples already collected during routine care, so no extr…

This early-stage trial will test a new drug called hydronidone, which is being developed for liver fibrosis caused by hepatitis B. Since patients often need to take antiviral drugs for hepatitis B, researchers want to see if hydronidone can be taken safely alongside four common a…

This study will look at 80 pregnant women with signs of liver issues, such as high liver enzymes or bilirubin, to find out which liver disorders are most common and how they affect both mother and baby. Researchers will track changes in liver health over time using blood tests an…

This study will compare two types of liver transplants: auxiliary (where part of the patient's own liver is left in place) and living donor (where a portion of a donor's liver is used). Researchers will track 100 patients to see which approach leads to better survival, fewer comp…

This study will enroll 2,000 Egyptian patients with chronic hepatitis B to find out how common antiviral drug resistance is and what factors make it more likely. Researchers will look at patients taking common antiviral drugs like tenofovir, entecavir, or lamivudine. The goal is …

This study will follow 100 adults with chronic liver disease who are hospitalized for sudden worsening of their condition. Researchers will track organ failure, recovery, and whether patients need a liver transplant or die within 6 months. The goal is to better understand how the…

This study will compare a new handheld device to the standard iLivTouch system for measuring liver stiffness and fat in 224 adults with chronic liver disease. Participants will be tested with both devices while lying down and sitting. The goal is to see if the handheld device is …

This study will look at 150 infants and children aged 1 month to 4 years who are admitted to a hospital gastroenterology unit with a gastrointestinal disease. The goal is to find out how common electrolyte disturbances (like low sodium or potassium) are in these children. By meas…